Anti-inflammatory aspects of Lidocaine: a neglected therapeutic stance for COVID-19

The impact of Lidocaine gel on TNF-α expression in surgically induced oral mucosal ulcers: an immunohistochemical analysis in rabbits

“…More so, Lidocaine can counteract the increased glycolysis and glycolytic capacity in macrophages that is caused by LPS [29]. In a previous study by Weinberg et, it was concluded that lidocaine, in supposition, is a potent anti-inflammatory agent, with properties that are often compared to non-steroidal anti-inflammatory drugs (NSAIDs) and steroids [30]. The current study's limitations were the lack of clinical trials to be compared.…”

Lidocaine reinforces the anti-inflammatory action of dexamethasone on myeloid and epithelial cells activated by inflammatory cytokines or SARS-CoV-2 infection

“…Although lidocaine usage to modulate inflammation in severe COVID-19 patients has been envisaged [ 48 ], there have been few concreted attempts so far. A case of a severe patient receiving i.v.…”

A case report of an 18-year-old receiving nebulized lidocaine for treatment of COVID-19 cough

“…Nebulized or inhaled lidocaine has been proposed for use in COVID-19 acute respiratory distress syndrome and associated cough given its anti-inflammatory effects. 26 , 27 , 28 However, there have been no subsequent reports of use in children with respiratory distress or failure secondary to COVID-19 infection. In our patient with COVID-19-associated cough, use of nebulized lidocaine was associated with decreased sedation needs for coughing episodes.…”